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ABSTRACT
Background. Since 2005, three human clinical trials have been performed with the Wearable Artificial Kidney (WAK) and
Wearable Ultrafiltration (WUF) device. The lack of an adequate vascular access (VA) has been pointed out as the main
limitation to their implementation. Based on the current level of understanding, we will make the first conceptual proposal
of an adequate VA suitable for the WAK and the WUF.
Methods. All the literature related to WAK and WUF was reviewed. Based on eight main publications the VA major
characteristics were defined: a mean blood flow of 100 mL/min; the capability to allow prolonged and frequent dialysis
treatments, without interfering in activities of daily living (ADL); safe and convenient connection/disconnection systems;
reduced risk of biofilm formation and coagulation; high biocompatibility. A research was done in order to answer to each
necessary technological prerequisites.
Results. The use of a device similar to a CVC with a 5Fr lumen, seems to be the most feasible option. Totally subcutaneous
port devices, like the LifeSite(R) or Dialock (R) systems can be a solution to allow WAK or WUF to operate continuously while
patients carry out their ADL. Recently, macromolecules that reduce the risk of thrombosis and infection and are integrated
into a CVC have been developed and have the capability of overcoming these major limitations.
Conclusion. With an adequate VA, portable HD devices can be acceptable options to address several unmet clinical needs of
HD patients.
Keywords: end-stage renal disease, renal replacement therapy, vascular access, wearable artificial kidney, wearable ultrafil-
tration device
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INTRODUCTION
In the last decade, the prevalence of the population on dialysis
has almost doubled and is expected to rise even more in the
coming years [1, 2]. Although there are a range of renal replace-
ment therapy (RRT) options, the majority of end-stage renal dis-
ease (ESRD) patients are treated intermittently with conventional
haemodialysis (HD). This RRT reduces the freedom and health-
related quality of life (HRQOL) of ESRD patients and is less physi-
ological, implying the use of numerous drugs to optimize all the
complications associated with chronic kidney disease.
Recently recognition of RRT limitations has given rise to increas-
ing interest in the development of totally portable HD devices. In
fact, the initial idea of the first portable HD device—the wearable ar-
tificial kidney (WAK)—goes back to the 1970s. However, implemen-
tation of WAK was limited by the technologies available at that time
[3–5]. The first trial with a WAK in animals was reported in 2005 [6]
and 2 years later it was tested in humans [7]. Gura et al. [8] described
the first wearable ultrafiltration (WUF) device to manage fluid over-
load. In 2016, Gura et al. [9] published the first 24-h WAK treatment
human clinical trial. Importantly, in all these trials there were no sig-
nificant cardiovascular changes or acid–base or electrolytic serum
disturbances and the target ultrafiltration (UF) was achieved.
Additionally, the involved ESRD patients reported significant satis-
faction with the WAK, owing to greater freedom (Table 1) [9].
In the future, WAK and WUF will require significant techno-
logical improvement in the currently used dialysis equipment
in order to allow adequate treatment oriented towards the
particular clinical and personal needs of each patient (Table 2)
[4, 10].
The development of an appropriate vascular access (VA)
with a mean blood flow of 100 mL/min has been identified as
the first and limiting challenge for implementation of WAK/
WUK treatment. Thus, over the last few years, multidisciplinary
discussions have emerged about the optimal VA for these porta-
ble devices. The possibilities proposed always revolved around
catheters for HD, the arteriovenous fistulas and grafts.
However, none of these vascular accesses seem to fulfil the
needs associated with the WAK: mobility, flexibility and re-
duced risk of complications. Therefore it seems necessary that
something new should emerge.
The aim of this study is to conceptualize the first proposal of
an adequate VA for the WAK and WUF.
MATERIALS ANDMETHODS
WAK/WUF VA
Currently, three main types of VA for HD are available, namely the
arteriovenous fistula (AVF), the graft and the central venous cathe-
ter (CVC). The AVF remains the preferred VA due to better out-
comes, namely less serious infections, lower morbidity and higher
survival rates [11]. However, it has been demonstrated that poorer
results with CVCs can be due to selection bias (CVCs tend to be
used in sicker patients), and the infection risk with venous cathe-
ters, especially in elderly patients, has been found to be relatively
low [12]. On the other hand, adherence to hand washing and cathe-
ter care protocols, such as those suggested by the US Centers for
Disease Control, has resulted in a marked reduction of overall dial-
ysis catheter infection rates [13]. Thus, in certain particular clinical
circumstances, the chronic CVC can remain a useful form of VA.
According to the main published literature related to WAK
and WUF (Tables 1 and 2), ideal WAK devices must be wearable
and confortable, allowing prolonged and frequent dialysis
treatments, without interference in the activities of daily living
[3–10]. Ideal WAK devices must be wearable and comfortable,
allowing prolonged and frequent dialysis treatments without
interference in the activities of daily living. Although AVF is the
preferred VA for HD, a small needle dislodgment can result in
haematoma or more severe complications such as vessel lacer-
ation and active bleeding. Given a mean AVF blood flow of
1000 mL/min, is easy to understand how an AVF laceration, if
not controlled, can result in patient death within minutes.
Therefore AVF is not a suitable VA for WAK/WUF systems. The
same complications may also occur with grafts.
Considering the previous WAK experiences, the expected
outcomes and possible complications, the use of a device simi-
lar to a chronic CVC currently seems to be the most feasible
option. A newer needle-free AV access device has been devel-
oped—the Hemaport (Hemapure, Uppsala, Sweden) system,
which comprises a titanium connector attached to a polytetra-
fluoroethylene graft [14]. The only clinical data available is from
a study involving six centres and 13 implanted devices. A mean
blood flow of 364 mL/min (ranging from 100–450 mL/min) was
reported. Fourteen percent required thrombosis interventions
to establish functional VA, and six devices had to be removed
due to insufficient flow, thrombosis and/or infections. Thus fur-
ther clinical evaluation is required to demonstrate potential
clinical advantages.
RESULTS
VA Port
One major consideration regarding CVCs is the port. This is the
point of contact of the CVC with the external environment and
also with the HD system. Considering the most frequent CVC
model, the external portion is likely to be at an increased risk of
physical damage and contamination, consequently leading to
infection and hospitalization. Additionally, this portion can also
be affected by changes in body position during HD treatments,
leading to erratic performance [15]. This knowledge gave rise
to the development of the first totally implantable HD access
systems, the LifeSite Hemodialysis Access System (Vasca,
Tewsbury, MA, USA) and the Dialock Hemodialysis Access
System (Biolink, Manfield, MA, USA) [16–20]. They are both
completely subcutaneous systems and have implantable struc-
tural components (including valves and cannulas) and do not
use a subcutaneous cuff.
The LifeSite system valve (Figure 1) comprises titanium,
stainless steel and silicon elements, which connect to a 12-Fr
silicon cannula and is placed in the central venous system. Its
utilization requires implantation of two valves: one for drawing
and the other for return of blood. The unique design of this
valve allows isolation of the cannula relative to the fluid path-
way when not in use. Blood access is made by a specific 14-
gauge cannulation set, using the same needle site for each dial-
ysis treatment, resulting in the development of a fibrous tissue
tract that eventually becomes insensitive to pain [15].
The Dialock system (Figure 2) consists of a single titanium
body with two internal valves and two attached cannulas that
are accessed via specially designed 15-gauge cannulation sets.
This system has an internal mechanism designed to prevent
needle dislodgement during dialysis.
The two subcutaneous systems are recommended to be
placed in the upper chest, preferably in the right internal jugular
vein, but they can also be positioned in other locations accord-
ing to each individual patient’s requirements. The right internal
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jugular vein is the preferred site because it offers a more direct
route to the right atrium, and CVC insertion and maintenance
into this vessel are associated with a lower risk of complications
compared with other sites [19].
Until now, the majority of the studies performed with
LifeSite and Dialock devices have demonstrated that they
have very good survival and a low risk of device-related
complications.
Schwab et al. [16] performed a 6-month prospective multi-
centre clinical trial to compare the efficacy and safety of the
LifeSite system with the Tesio-Cath HD CVC. The main findings
of the study were that mean blood flow was significantly higher
with LifeSite than with the Tesio-Cath (358.7 versus 331.8 mL/
min; P< 0.001); the device-associated infection rate was signifi-
cantly lower for the LifeSite group, where 70% isopropyl alcohol
was used as an antimicrobial solution, compared with the
Tesio-Cath group (1.3 versus 3.3 events/1000 patients-days;
P< 0.05) and the LifeSite group with 70% isopropyl alcohol also
needed significantly fewer thrombolytic infusions than the
Tesio-Cath group (P¼ 0.0295).
In a 12-month multicentric prospective study, Rosenblatt
et al. [20] enrolled 68 patients requiring HD and compared the
performance between the LifeSite and Tesio-Cath systems. In
the LifeSite group, a lower number of device-related adverse
events were observed (P < 0.016), there was a lower need for
thrombolytic infusions (P < 0.002) and, importantly, fewer de-
vice-related infections were reported (P < 0.013) when com-
pared with the Tesio-Cath group. After censoring for planned
removals, the LifeSite device also had a significantly higher
probability of device survival at 1 year.
Preliminary clinical results with the Dialock device were
published by Canaud et al. [21] in 10 HD patients. The mean sur-
vival of the device was 5.7 (1.3–9.6) months. They identified
three cases of bacteraemia that occurred in the early phase of
the study and were solved with antibiotic therapy, but no device
was removed. The mean blood flow was 3076 3.3 mL/min, ve-
nous pressure was 195639 mmHg and the Kt/V delivered was
1.3660.03. In a later study, Canaud et al. [22] reported the
results of this device in 23 HD patients. The average duration of
the device was 11 (range 4–19) months. The Dialock was re-
moved in two patients due to infection that involved the skin,
the tissue and the device and had no response to topical or sys-
temic antibiotic therapy. The mean Kt/V was 1.4860.23.
Previous studies demonstrated that the Dialock and the
LifeSite systems could be good options for patients being
treated with chronic HD. However, most of these studies date
back to the 2000s, with the latest study being published in 2008.
This may be attributed primarily to the fact that CVCs are con-
sidered the ‘last line’ of VA for the current most frequent option
of short intermittent and in-centre HD. However, with the de-
velopment of fully portable HD devices and more biocompatible
materials with reduced risk of infection and thrombosis, these
devices should be reconsidered. In the case of the WAK and
WUF, given the possibility of using a reduced lumen CVC, it may
be possible to significantly reduce the dimensions of both these
devices. On the one hand, the placement becomes easier and
can be done in a way similar to a conventional tunnelled CVC,
avoiding a surgical intervention. On the other hand, it is now
also possible to increase comfort and reduce its aesthetic im-
pact, as is the case with ports of CVCs used in chemotherapy.
Another limiting factor associated with the use of these devices
is that they require needles, which is not the case with the cur-
rent CVCs, and may cause pain and discomfort. This also pro-
vides a window of opportunity for the development of punch/
connection systems that do not use needles and that are cer-
tainly the future in HD. Finally, the use of these systems proba-
bly has a higher associated cost. Given the high percentage of
patients initiating HD using CVCs, if the use of these devices
becomes widespread, it could entail very high costs. However, if
the use of these devices is made with the WAK and WUF in
mind, and they are miniaturized, their cost may possibly be
reduced.
Although subcutaneous systems are associated with a re-
duced risk of infection, aseptic measures have to be carefully
taught and reinforced. Thus, similar to tunnelled CVCs, proto-
cols for all aspects of these implantable devices need to be
implemented.
VA Lumen
In order to select the correct lumen of the catheter, from a hae-
modynamic point of view, it is necessary to take into account
the Hagen–Poiseuille law:
DP¼ ð128 gQ LÞðp d4Þ
where DP is the pressure drop along the catheter, g is the viscos-
ity, Q is the blood flow, L is the catheter length and d is the inner
diameter of the catheter.
Table 2. Technical components and future improvements in theWAK andWUF
Component Requirement/future improvement
Pumping system: blood
pumps, fluid pumps
Miniaturized and wearable shape; no haemolysis; high biocompatibility
Dialysis membrane Miniaturized and wearable shape; mimics physiological functions of the nephron; allows por-
tability; a geometry that allows for a replaceable disposable pump, an effective surface area
and pore distribution for longer treatment time; no haemolysis; high biocompatibility
Dialysate regenerating system Lightweight; easily replaceable sorbent cartridge; replace smart sorbent material with high
adsorption capacity of uremic toxins; accurately monitor the dialysate composition (with
pH, temperature, volume, composition and bacterial contamination sensors)
Patient monitoring system Monitor fluid balance, pressure in the dialysis system, pump power battery, blood leakage, bub-
ble detection and VA disconnection; done by remote control
Battery Small and light; provides enough energy for a significant period of time
VA Allows comfortable, prolonged and frequent dialysis treatments without interference in activi-
ties of daily living; safe and convenient connection/disconnection system; reduced risk of
biofilms formation and coagulation; high biocompatibility
Future path for WAK and WUF VA | 303
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/12/2/300/5103441 by guest on 06 M
ay 2020
Considering that blood viscosity does not vary much (it
depends on blood characteristics like haematocrit and protein
concentration), the main parameters affecting the pressure
drop are the geometric characteristics of the catheter (diameter
and length). In particular, the pressure drop is proportional to
the fourth power of the diameter. Consequently, it would be de-
sirable to increase the diameter in order to reduce as much as
possible the pressure drop and to avoid catheter collapse.
On the other hand, the catheter diameter cannot be exces-
sively large because it may fill the vein too tightly, possibly lead-
ing to damage of vein wall, together with an increased risk of
stenosis or thrombosis. A good compromise between these two
aspects needs to be reached.
In Figure 3, a theoretical Hagen–Poiseuille law–based selec-
tion of the minimum diameter of a single-lumen catheter for a
wearable device is represented. In particular, the following
assumptions were considered:
• desirable blood flow of 100 mL/min;
• constant and standard length of the catheter for adults
(L ¼ 19 cm) and
• patient venous pressure of 10 mmHg.
The pressure drop between the patient vessel and the access
pressure detecting point in the extracorporeal circuit is due al-
most entirely to the catheter.
On the access side of the catheter, more critical for the selection
than the return one, the minimum pressure difference (DP) along
the length of the device should not exceed 350 mmHg [23], to avoid
haemolysis and catheter collapse. However, this value does not take
into account blood flow that is not uniformly laminar, the curvilin-
ear deformation of the catheter after implantation and the tubing
roughness. For these reasons, a strict safety factor of 2 was taken
into account to determine an acceptable value of pressure drop, DP0:
DP’ ¼ DP
2
¼ 175 mmHg:
Under these conditions, a minimum size of a 5-Fr single-lumen
catheter is required, matching technical requirements and clini-
cal/ergonomics needs.
VAMaterials
The improvement of silicone materials that was observed in the
1940s gave rise to more biocompatible, relatively non-thrombo-
genic, chemically resistant CVCs that had better longevity and
fewer complications such as thrombosis and infection [24].
Advances in material technology have resulted in the transition
from silicone-based dialysis catheters to the use of polyurethane.
Polyurethanes are polymers with thermoplastic [25]. Silicone and
polyurethane CVCs are not significantly different in terms of du-
ration and function. However, polyurethane has a greater tensile
strength, allowing a larger inner lumen with the same outer di-
ameter, which improves the flow rate. Polyurethane/polycarbon-
ate copolymers (such as carbothane) are the most recent
generation of CVC materials. They offer greater strength for lon-
gevity and softness for flexibility and patient comfort and still re-
tain all the advantages of polyurethane. Additionally, these
copolymers are also resistant to iodine, peroxide and alcohols.
Coatings
Although there has been significant developments in CVC
materials, making them more biocompatible and reducing the
FIGURE 2: Dialock system. Adapted from Levin and Ronco [15].
FIGURE 1: The LifeSite system. Adapted from Levin and Ronco [15].
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rate of infection and thrombosis, these still remain the most
common complications associated with this type of VA. Two
different kinds of CVC surface coverings were developed:
antithrombotic and antimicrobial coatings.
Heparin is the most studied antithrombotic substance and
coverage of the CVC lumen allows this molecule to exert its activ-
ity in three main ways: locally inactivating the coagulation cas-
cade, electrostatically repulsing the charged platelets and
decreasing the adhesion of bacteria to the CVC through their hy-
drophobic interactions [26]. Until now, studies that showed the
efficacy and safety of heparin utilization in decreasing bacterae-
mias and colonizations were mainly performed in intensive care
units [26]. The number of studies in HD patients is limited.
There are few publications regarding the use of antibiotic-
impregnated catheters (AICs) in the dialysis population; how-
ever, they have demonstrated significant anti-infective benefit.
The most commonly studied AIC is the combination of mino-
cycline and rifampin covering the inner and outer surfaces of
the catheter. Raad et al. [27] performed a multicentric, random-
ized clinical trial with 281 hospitalized patients who needed
triple-lumen CVCs: 147 catheters were pretreated with tridode-
cylmethylammonium chloride and coated with minocycline
and rifampin and 151 non-coated catheters were used as con-
trols. Coated CVCs demonstrated a statistically significant supe-
riority in colonization (26 versus 8%; P< 0.001) and catheter-
related bloodstream infection (0 versus 5%; P< 0.01) and a mul-
tivariate logistic regression analysis showed that coating cathe-
ters with minocycline and rifampin is an independent
protective factor against catheter-related colonization (P< 0.05).
However, there can be two main problems associated with anti-
biotic coating: the possibility of antibiotic resistance and antibi-
otic impregnation longevity [25].
The understanding of the key role of the fibrin sheath in the de-
velopment of CVC-related thrombosis and bacteraemia parallel to
the evolution in nanotechnology allowed the recent emergence of
very promising CVC coatings. In a recently published in vitro study,
Hugoni et al. [28] evaluated fibronectin, monocyte response and
thrombus formation on two surface-modified polyetherurethanes.
They used two surface modifiers: an anionic/dihydroxyl oligomeric
additive that enables cell adhesion and a fluorinated polypropylene
oxide oligomer known to reduce platelet adhesion. The results of
the study demonstrated that these molecules promote an anti-
inflammatory character, with longer clotting times, suggesting their
potential for the reduction of thrombus formation.
Endexo technology [developed by Interface Biologic and cur-
rently licensed to AngioDynamics for VA devices (http://www.
interfacebiologics.com/endexo.htm)] consists of surface-modi-
fying macromolecules that are permanently combined with the
polyurethane in the inner and outer surface of the catheter.
These macromolecules appear to be similar to anionic/dihy-
droxyl oligomeric additives that reduce the adhesion and acti-
vation of blood proteins and components, thereby reducing
thrombus formation.
Similarly, the development of anti-infective polymers may con-
tribute to the reduction of infection rates associated with the use of
CVCs. In this case, however, the potential for developing resistance
of microbial agents should always be taken into account.
DISCUSSION
Possible future path for WAK andWUF VA
ESRD prevalence is expected to more than double in the next
decade [2]. Although renal transplantation is considered the
best option for ESRD patients, there are still several limitations
to its wider use. Portable HD devices can be acceptable options
to address several unmet clinical needs of HD patients.
However, their implementation depends primarily on the
FIGURE 3: Graph comparing the reachable blood flow and pressure drop inside the catheter. Coloured lines represent catheters with different lumen sizes. Only single-
lumen catheters were considered. Green area represents the acceptable range between DP and catheter size for the desired blood flow. For blood flow of 100 mL/min, a
5 Fr is the minimum acceptable size of the lumen.
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development of innovative VA systems. Based on previous
studies, completely subcutaneous port devices, similar to the
LifeSite and Dialock systems, seem to be the best solution that
allows the WAK or WUK to operate continuously while keeping
patients mobile enough to carry out their daily life activities
without any impediments. The LifeSite system has more stud-
ies proving its safety and superiority comparable to the Tesio-
Cath; the Dialock system can also provide some advantage in
terms of convenience and its safety mechanism prevents nee-
dle dislodgement during dialysis. However, these systems need
to be further improved upon in terms of miniaturization, im-
proved biocompatibility and reduced risk of infection and
thrombosis. Thus their placement will eventually become eas-
ier, patient comfort will be improved and aesthetic impact will
be reduced. The development of punch/connection systems
that do not use needles and can be controlled by the patient
could become emerging opportunities for development. These
systems should support patient mobility during HD treatment.
According to previous studies, the blood flow rate required for
the WAK/WUF at optimal usage is 100 mL/min, which allows
the size of the CVC lumen to be significantly reduced. So,
according to the Hagen–Poiseuille law, two 5-Fr single-lumen
catheters composed of polyurethane/polycarbonate polymers
could be used. Different kinds of coatings have been studied,
namely heparin and antibiotics such as minocycline and ri-
fampin. However, use in patients with ESRD is still not well
understood. Recent advances in nanotechnology have given
rise to the development of macromolecules that are added to
the inner and outer surfaces of the CVC and thus may reduce
the risk of thrombosis. This is the basis for Endexo technology
(http://www.interfacebiologics.com/endexo.htm). The use of
these macromolecules may make it possible to overcome throm-
bosis, which is one of the major limitations associated with
CVC use. In conclusion, a prototype of the WAK/WUF VA
should be developed along the lines of a miniaturized version of
the Dialock system made with a biocompatible substance and
ideally should be free from needle use. This system could be
placed in the right internal jugular vein (similar to a tunnelled
CVC). The miniaturized system would connect to two 5-Fr single-
lumen catheters composed of polyurethane/polycarbonate poly-
mers with antithrombotic/anti-infectious macromolecules
(Figure 4).
CONCLUSION
Despite significant technological evolution in RRT, HD contin-
ues to be associated with poor morbidity, mortality and HRQOL
outcomes in ESRD patients. The development of WAK and WUF
devices may be an important turning point in the care of ESRD
patients. The development of an appropriate VA with reduced
risk of complications is the first step in making the WAK and
WUF feasible, safe, efficacious, cost-effective and convenient
therapies for needy patients.
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